Potential anti-TB investigational compounds and drugs with repurposing potential in TB therapy: a conspectus

摘要: The latest WHO report estimates about 1.6 million global deaths annually from TB, which is further exacerbated by drug-resistant (DR) TB and comorbidities with diabetes HIV. Exiguous dosing, incomplete treatment course, the ability of tuberculosis bacilli to tolerate survive current first-line second-line anti-TB drugs, in either their latent state or active state, has resulted an increased prevalence multidrug-resistant (MDR), extensively (XDR), totally (TDR-TB). Although a better understanding microanatomy, genome, transcriptome, proteome, metabolome, discovery few novel promising drug targets diagnostic biomarkers late, no new candidates have been approved for routine therapy over 50 years, only bedaquiline, delamanid, pretomanid recently receiving tentative regulatory approval. Considering this, alternative approaches identifying possible candidates, effectively eradicating both replicating non-replicating Mycobacterium tuberculosis, are still urgently required. Subsequently, several antibiotic non-antibiotic drugs known indications (TB targeted non-TB targeted) now being repurposed and/or derivatized as antibiotics use therapy. Insights gathered here reveal that more studies focused on drug-drug interactions between licensed potential lead need be prioritized. This write-up encapsulates most recent findings regarding investigational compounds repurposing